Who We Are

BioIntercept is developing a proprietary exosome-based delivery platform therapy derived from stem cells that enables better targeted cell regeneration across tissue types, delivery of therapeutic RNA, peptides, and proteins, and penetration of biological barriers like the blood-brain barrier.

• Platform Solution: BioIntercept solves drug delivery problems through a platform that offers high therapeutic precision and reduced immunogenicity.


• Key Differentiators: Platform scalability, natural delivery vector, and cross-tissue targeting capabilities set us apart from competitors.


• Versatile Administration: Our therapy can be administered through multiple routes—intravenous, intranasal, nebulizer, sublingual, and local injections targeting various indications.


• Market Opportunity: The total addressable market for our platform therapies is $280 billion, with immediate addressable market of $220 billion in Regenerative Medicine across 6 critical need indications.

Boosting Natural Healing

Using special exosomes from our advanced stem cells, our platform accurately finds and helps repair damaged tissues. This leads to faster healing and restored function in areas like heart muscle after a heart attack, and brain cells in diseases like Alzheimer's.

Precise Drug Delivery

Designed with special surface proteins, our exosomes can carry and deliver various treatments, like genetic instructions (for gene editing or silencing) and special proteins. This focused delivery reduces side effects and makes treatments safer and more effective than traditional methods.

Breaking Through Barriers

Our exosome technology is uniquely designed to get past tough biological barriers, like the blood-brain barrier (BBB) and eye membranes. This breakthrough opens up new ways to treat conditions that were previously untreatable, such as certain brain tumors, Alzheimer's, and various eye diseases, by delivering medicine directly to hard-to-reach areas.

Reach out to us to learn more:

CONTACT US